Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents

Schizophrenia Research

Volumn 125, Issue 1, 2011, Pages 77-87

  Abekawa, Tomohiro ^a,b   Ito, Koki ^b   Nakagawa, Shin ^b   Nakato, Yasuya ^b   Koyama, Tsukasa ^b  

^a Kotoku kai Aiko Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Aripiprazole; Haloperidol; Methamphetamine; PPI; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; GLUTAMIC ACID; HALOPERIDOL; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; LOCOMOTION; MALE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; APOPTOSIS; BEHAVIORAL SYMPTOMS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; HALOPERIDOL; IN SITU NICK-END LABELING; INHIBITION (PSYCHOLOGY); MALE; METHAMPHETAMINE; MICRODIALYSIS; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PIPERAZINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; STARTLE REACTION;

EID: 78650286336     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.08.011     Document Type: Article

References (51)

1. Abekawa T., Honda M., Ito K. Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and α1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats. Psychopharmacology 2003, 169:247-256.
2. Abekawa T., Ito K., Koyama T. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 2006, 374:177-193.
3. Abekawa T., Ito K., Nakagawa S., Nakato Y., Koyama T. Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex. Schizophr. Res. 2008, 101:84-94.
4. Arvanov V.L., Liang X., Schwartz J. Clozapine and haloperidol modulate N-methyl-d-aspartate- and non-N-methyl-d-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 1997, 283:226-234.
5. Bai O., Zhang H., Li X.-M. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res. 2004, 1010:81-86.
6. Bakshi V.P., Geyer M.A. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J. Neurosci. 1998, 18:8394-8401.
7. Bakshi V.P., Swerdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 1994, 271:787-794.
8. Benes F.M., Walsh J., Bhattacharyya S., et al. DNA fragmentation decreased in schizophrenia but not bipolar disorder. Arch. Gen. Psychiatry 2003, 60:359-364.
9. Borgwardt S.J., Dickey C., Pol H.H., Whitford T.J., DeList L.E. Workshop on defining the significance of progressive brain change in schizophrenia: December 12, 2008 American College of Neuropsychopharmacology (ACNP) all-day satellite, Scottsdale, Arizona. The rapporteurs' report. Schizophr. Res. 2009, 112:32-45.
10. Buttner N., Bhattacharyya S., Walsh J. DNA fragmentation is increased in non-GABAergic neurons in bipolar disorder but not in schizophrenia. Schizophr. Res. 2007, 93:33-41.
11. Chakos M.H., Schobel S., Gu H., et al. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br. J. Psychiatry 2005, 186:26-31.
12. Chen M.J., Russo-Neustadt A.A. Exercise activates the phosphatidylinositol 3-kinase pathway. Brain Res. Mol. Brain Res. 2005, 135:181-193.
13. Cosi C., Waget A., Rollet K., Tesori V., Newman-Tancredi A. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 2005, 1043:32-41.
14. DeLisi L.E. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr. Bull. 2008, 34:312-321.
15. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 1992, 119:493-501.
16. Glantz L.A., Gilmore J.H., Lieberman J.A., et al. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr. Res. 2006, 81:47-63.
17. Gleason S.D., Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 1997, 129:79-84.
18. Hetts S.W. To die or not to die: an overview of apoptosis and its role in disease. J.A.M.A. 1998, 279:300-307.
19. Jarskog L.F., Selinger E.S., Lieberman J.A., et al. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am. J. Psychiatry 2004, 161:109-115.
20. Jarskog L.F., Glantz L.A., Gilmore J.H., et al. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog. Neuro-Psychopharmacol Biol. Psychiatry 2005, 29:846-858.
21. Jentsch J.D., Tran A., Taylor J.R. Prefrontal cortical involvement in phencyclidine-induced activation of mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology 1998, 138:89-95.
22. Kadota T., Kadota K. Neurotoxic morphological changes induced in the medial prefrontal cortex of rats behaviorally sensitized to methamphetamine. Arch. Histol. Cytol. 2004, 67:241-251.
23. Kane J.M., Leucht S., Carpenter D., Dochery J. The Expert Consensus Guideline Series: optimizing pharmacologic treatment of psychotic disorders. J. Clin. Psychiatry 2003, 64(suppl 12):52-54.
24. Kasai K., Shenton M.E., Salisbury D.F., et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am. J. Psychiatry 2003, 160:156-164.
25. Laruelle M., Abi-Dargham A., Van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:9235-9240.
26. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phase. Biol. Psychiatry 1999, 46:56-72.
27. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychoharmacology 1999, 20:612-627.
28. Li Z., Ichikawa J., Dai J., Meltzer H.Y. Aripiprazole, a novel drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 2004, 493:75-83.
29. Lieberman J.A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry 1999, 46:729-739.
30. Lieberman J.A. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J. Clin. Psychiatry 1999, 60:9-12.
31. Lieberman J.A., Tollefson G.D., Charles C., et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 2005, 62:361-370.
32. Lu W., Monteggia L.M., Wolf M.E. Withdrawal from repeated amphetamine administration reduces NMDAR1 expression in the rat substantia nigra, nucleus accumbens and medial prefrontal cortex. Eur. J. Neurosci. 1999, 11:3167-3177.
33. Martins M.R., Petroniho F.C., Gomes K.M., et al. Antipsychotic-induced oxidative stress in rat brain. Neurotox. Res. 2008, 13:63-69.
34. Narendran R., Frankle W.G., Mason N.S., et al. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB457 and [11C]fallypride. Synapse 2009, 63:447-461.
35. Ninan I.P.E., Jademark K.E., Wang R.Y. Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 2003, 48:66-79.
36. Pantelis C., Velakoulis D., McGorry P.D., et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281-288.
37. Park S.W., Lee J.G., Ha E.K., et al. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur. Neuropsychopharmacol. 2009, 19:356-362.
38. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1997, Academic Press, USA. Third edition.
39. Pukrop R., Schultze-Lutter F., Ruhrmann S., et al. Neurocognitive functioning in subjects at risk for a first episode of psychosis compared with first- and multiple-episodes schizophrenia. J. Clin. Exp. Neuropsychol. 2006, 28:1388-1407.
40. Schwabe K., Koch M. Role of the medial prefrontal cortex in N-methyl-D-aspartate receptor antagonist induced sensorimotor gating deficit in rats. Neurosci. Lett. 2004, 355:5-8.
41. Selemon L.D., Begovic A., Goldman-Rakic P.S., et al. Amphetamine sensitization alters dendrite morphology in prefrontal cortical pyramidal neurons in the non-human primate. Neuropharmacology 2006, 32:919-931.
42. Sheitman B.B., Lieberman J.A. The natural history and pathophysiology of treatment resistant schizophrenia. J. Psychiatr. Res. 1998, 32:143-150.
43. Sills T.L. Amphetamine dose dependently disrupts prepulse inhibition of the acoustic startle response in rats within a narrow time window. Brain Res. Brain Res. Bull. 1999, 48:445-448.
44. Swerdlow N.R., Bakshi V.P., Geyer M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J. Pharmacol. Exp. Ther. 1996, 279:1290-1299.
45. Ukai W., Ozawa H., Tateno M., et al. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J. Neural Transm. 2004, 111:667-681.
46. Van Haren N.E., Hulshoff Pol H.E., Schnack H.G., et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 2007, 32:2057-2066.
47. Whitford T.J., Grieve S.M., Farrow T.F., Gomes L., Brennan J., Harris A.W., Gordon E., Williams L.M. Progressive grey matter atrophy over the first 2-3years of illness in first-episode schizophrenia: a tensor-based morphometry study. Neuroimage 2006, 32:511-519.
48. Yamamoto H., Kitamura N., Lin X.H., et al. Differential changes in glutamatergic transmission via N-methyl-D-aspartate receptors in the hippocampus and striatum of rats behaviorally sensitized to methamphetamine. Int. J. Neuropsychopharmacol. 1999, 2:155-163.
49. Yang T.T., Wang S.J. Effects of haloperidol and clozapine on glutamate release from nerve terminals isolated from rat prefrontal cortex. Synapse 2005, 56:12-20.
50. Yang T.T., Wang S.J. Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia. Synapse 2008, 62:804-818.
51. Yuan J., Yankner B.A. Apoptosis in the nervous system. Nature 2000, 407:802-809.